BioNTech SE, a German biotechnology company, is on a mission to develop and commercialize immunotherapies for various infectious diseases and cancer. The company's FixVac product candidates are making impressive strides in clinical trials, including BNT111 in Phase II for advanced melanoma, BNT112 in Phase I/IIa for prostate cancer, and BNT113 in Phase II to treat HPV 16+ head and neck cancers. Additionally, the company's BNT122 is promising in Phase II for first-line melanoma and in Phase I for multiple solid tumors, while BNT131 is being tested in Phase I clinical trials for multiple solid tumors. Other developments include BNT311 in Phase II clinical trials to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, in Phase II clinical trials to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors, among many other potential immunotherapy treatments in development. BioNTech SE is actively collaborating with major industry players such as Pfizer, Genentech, and Sanofi, among others, positioning the company at the forefront of promising advances in cancer research and treatment.
BioNTech SE's ticker is BNTX
The company's shares trade on the NASDAQ stock exchange
They are based in Mainz, Germany
There are 1001-5000 employees working at BioNTech SE
It is https://biontech.de/
BioNTech SE is in the Healthcare sector
BioNTech SE is in the Biotechnology industry
The following five companies are BioNTech SE's industry peers:
- China Biologic Products, Inc.